UNSPSC 51392301: Debrisoquine

This classification denotes an adrenergic agent, antihypertensive agent, and sympatholytic with the molecular formula C10H13N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X31CDK040E, chemically known as 1,2,3, 4-tetrahydro-isoquinoline-2-carboxamidine sulfate but generally known as debrisoquine, which bears US NIH Compound Identifier 2966. European Medicines Agency schedules Debrisoquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06928MIG.

World Health Organization schedules debrisoquine in its Anatomical Therapeutic Chemical (ATC) Classification. DEBRISOQUINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule debrisoquine under HS 29334990 and SITC 51575. SMILES: C1CN(CC2=CC=CC=C21)C(=N)N.

UNSPSC 51392301 Debrisoquine is a Commodity code that maps to pharmaceutical procurement activity at the state and local level, though recent opportunities show minimal alignment with the code's nominal scope. The recent solicitations tagged under this code do not involve debrisoquine itself but instead reflect broader pharmaceutical and health-services procurement — specifically naloxone acquisition and direct-to-manufacturer prescription program design. State and local governments are using this code family to procure emergency pharmaceutical products and to explore alternative pharmacy benefit delivery models that bypass traditional pharmacy benefit managers and wholesalers. Issuing bodies range from county health departments (Seminole County, Florida) to state health commissions (Texas Health and Human Services Commission), reflecting the medical and public-health procurement focus at multiple governance levels.

Geographically, recent activity centers on Florida and Texas. Seminole County's IFB 60459723LAS (posted June 30, 2026, with a response deadline of July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the county's Community Health Building, with fixed-fee pricing and a two-year initial term plus one-year renewal option. The Texas HHS Commission issued RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional PBM and group purchasing organization channels, targeting self-insured employers and government health plans. The code shows limited recent activity and poor alignment with its nominal pharmaceutical substance; firms should verify code assignment before responding to solicitations and focus on the actual products and services being procured rather than the code name.